Kenvue Competitive Intelligence & Landscape

Kenvue (kenvue.com) is a global consumer health company dedicated to the extraordinary power of everyday care. The company focuses on connecting care across the world through its global reach and diverse portfolio of iconic brands. Their mission is to empower individuals to engage more fully with the world by providing trusted daily care solutions rooted in science.

Kenvue offers a wide range of well-known consumer health products, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena®, Nicorette®, and Tylenol® [https://investors.kenvue.com/overview/]. These brands are utilized by approximately 1.2 billion people globally in their daily routines [https://www.kenvue.com/brands]. The company emphasizes scientific precision and thoughtful everyday care, innovating to bring real solutions into communities, homes, and hands.

Kenvue debuted on the New York Stock Exchange (NYSE: KVUE) on May 4, 2023 [https://www.kenvue.com/what-is-kenvue] and became a fully independent company following its final separation from Johnson & Johnson on August 23, 2023 [https://www.kenvue.com/media/kenvue-becomes-a-fully-independent-company]. Headquartered in Skillman, New Jersey, Kenvue employs over 20,000 global team members who are united by a commitment to solving everyday care needs [https://www.kenvue.com/what-is-kenvue].

The target market for Kenvue encompasses consumers worldwide, as its brands have been caring for generations around the globe for 140 years [https://kenvue.com/]. They aim to provide solutions for daily needs, ensuring that when people can count on care every day, it not only makes them well but makes them whole.

Kenvue's value proposition centers on delivering science-backed care that is at the core of consumers' daily lives at every stage.

Kenvue operates as a global consumer health company, focusing on a diverse portfolio of iconic brands rather than offering direct pricing plans or tiers for its products to end-consumers. The company's business model revolves around selling consumer health products that are integrated into daily care routines worldwide. These products span categories like skin health, baby care, and pain relief, and include well-known names such as Aveeno®, Neutrogena®, Tylenol®, Listerine®, Johnson's®, and Band-Aid® Brand. The emphasis is on delivering meaningful, personal health solutions backed by science and over 135 years of heritage, touching the lives of approximately 1.2 billion people globally.

There is no indication of pricing plans, tiers, or free versus paid features in the context of Kenvue's direct offerings to consumers, as it functions as a manufacturer and distributor of consumer goods. Instead, the company's financial information is relevant to investors, with investor data being delayed by 20 minutes as of July 2, 2026. This suggests that financial performance and stock pricing are publicly available for investors, rather than product-specific pricing for consumers. For its suppliers, Kenvue requires all invoices to be submitted through its preferred e-Invoicing provider, Tungsten Network, at no additional cost to the supplier, indicating a specific operational detail for business partners.

Recent news from Kenvue highlights product innovations and corporate activities rather than pricing changes. For example, recent announcements include Tylenol® introducing PainTalk, Kenvue beating its 2025 packaging goal with more sustainable innovations for brands like Neutrogena®, Aveeno®, OGX®, and Zyrtec®, and Listerine® introducing a range of mouthwash intensities. The company also reports quarterly results and declares cash dividends, reflecting its financial operations as a publicly traded entity. The content consistently focuses on brand strength, scientific backing, and global reach in the consumer health market.

Kenvue actively recruits for a diverse range of roles, emphasizing its commitment to building an agile and inspired team focused on "care-forward solutions" [https://jobs.kenvue.com/]. The company maintains a dedicated careers portal [https://www.kenvue.com/careers] and encourages individuals to join its talent community to receive job updates [https://jobs.kenvue.com/talent-community].

Kenvue's hiring patterns indicate a strategic focus on various business functions, from brand management to supply chain and digital innovation. Notable open positions include an Associate Brand Manager, US Pain in Summit, New Jersey [https://jobs.kenvue.com/associate-brand-manager-us-pain/job/3B33057F95615B9AF6FB47E003FD1056], and a Master Data Analyst, also in Summit, New Jersey [https://jobs.kenvue.com/master-data-analyst/job/F8180C962FAD24EF64BBB00F72720347]. The presence of roles like Lead Digital Product Development – Agentic AI in Bangalore, India [https://jobs.kenvue.com/lead-digital-product-development/job/09E172C6B2228894D087C7B4649D35FD], signals an investment in advanced technology and global digital transformation.

Furthermore, Kenvue shows a strong commitment to developing future talent through programs for students and graduates [https://jobs.kenvue.com/students-and-graduates]. An example of this is the Supply Chain Fall 2026 Co-op (Multiple Positions) in Summit, New Jersey [https://jobs.kenvue.com/supply-chain-fall-2026-co-op-multiple-positions/job/1DDD254B45BEE876C5CC69A48BA243FE], which aims to cultivate leaders within its Supply Chain Management organization. There is no information available from the provided sources indicating any recent layoffs at Kenvue; instead, the focus is clearly on active recruitment and career growth.

Kenvue (kenvue.com) has demonstrated fluctuating financial performance, reporting a net sales increase of 3.2% and organic sales growth of 1.2% in Q4 2025. However, for the full fiscal year 2025, the company experienced a decline in net sales by 2.1% and organic sales by 2.2%. Despite this, Kenvue saw its diluted EPS at $0.17 and adjusted diluted EPS at $0.27 in Q4 2025, with full-year 2025 diluted EPS at $0.76 and adjusted diluted EPS at $1.08 [https://investors.kenvue.com/financial-news/news-details/2026/Kenvue-Reports-Fourth-Quarter-and-Full-Year-2025-Results/default.aspx]. In the first quarter of 2026, Kenvue reported net and organic sales growth for the second consecutive quarter, alongside improvements in gross margin, operating margin, and EPS [https://www.kenvue.com/media/kenvue-first-quarter-2026-results].

Financially, Kenvue also provided an outlook for FY'25 after reporting full-year 2024 results, where net sales increased by 0.1% to $15.5 billion and organic sales grew by 1.5%. Its gross profit margin improved by 200 basis points in FY'24, with diluted EPS at $0.54 and adjusted diluted EPS at $1.14 [https://investors.kenvue.com/financial-news/news-details/2025/Kenvue-Reports-Full-Year-and-Fourth-Quarter-2024-Results/]. The company maintains its investor relations portal where it provides access to quarterly and annual reports [https://investors.kenvue.com/financials-reports/quarterly-results/default.aspx].

In terms of fundraising and M&A activity, Kenvue completed its initial public offering (IPO) on the New York Stock Exchange (NYSE) under the symbol “KVUE” at $22.00 per share. This included the full exercise of underwriters’ option to purchase additional shares, making it the world’s largest pure-play consumer health company by revenue at the time [https://investors.kenvue.com/financial-news/news-details/2023/Kenvue-Announces-Closing-of-Initial-Public-Offering/default.aspx]. Subsequently, Kenvue became the target of an acquisition, with Kimberly-Clark Corporation announcing an agreement on November 3, 2025, to acquire all outstanding shares of Kenvue common stock. This cash and stock transaction valued Kenvue at an enterprise value of approximately $48.7 billion [https://investors.kenvue.com/financial-news/news-details/2025/Kimberly-Clark-to-Acquire-Kenvue-Creating-a-32-Billion-Global-Health-and-Wellness-Leader/default.aspx]. The acquisition aims to create a global health and wellness leader [https://investors.kenvue.com/overview/default.aspx].

Kenvue actively participates in a variety of industry events, conferences, and investor briefings. For instance, Kenvue's leadership, including CEO Thibaut Mongon, CFO Paul Ruh, and Chief Growth Officer Charmaine England, presented at the Consumer Analyst Group of New York (CAGNY) Conference on February 19, 2025 ["Kenvue to webcast presentation at the Consumer Analyst Group of New York Conference"(https://www.kenvue.com/media/webcast-presentation-consumer-analyst-group-of-new-york-conference), "Kenvue to Webcast Presentation at the Consumer Analyst Group of New York Conference"(https://investors.kenvue.com/financial-news/news-details/2025/Kenvue-to-Webcast-Presentation-at-the-Consumer-Analyst-Group-of-New-York-Conference)].

Kenvue has also been a notable presence at investor and consumer-focused conferences. In May 2024, the company announced its participation in Deutsche Bank's dbAccess Global Consumer Conference in Paris, France ["Kenvue announces participation in Deutsche Bank's dbAccess Global Consumer Conference"(https://www.kenvue.com/media/kenvue-participation-in-deutsche-banks-dbaccess-global-consumer-conference), "Kenvue Announces Participation in Deutsche Bank's dbAccess Global Consumer Conference"(https://investors.kenvue.com/financial-news/news-details/2025/Kenvue-Announces-Participation-in-Deutsche-Banks-dbAccess-Global-Consumer-Conference/)]. Additionally, Kenvue participated in the Barclays Global Consumer Staples Conference in Boston, Massachusetts, in August 2024 ["Kenvue announces participation in the Barclays Global Consumer Staples Conference"(https://www.kenvue.com/media/kenvue-barclays-global-consumer-staples-conference)], and the Morgan Stanley Global Consumer & Retail Conference in New York City in November 2024 ["Kenvue announces participation in the Morgan Stanley Global Consumer & Retail Conference"(https://www.kenvue.com/media/morgan-stanley-global-consumer-retail-conference-2024)].

Beyond financial and consumer insights, Kenvue engages in scientific and medical forums. The company showcased new clinical data on skin longevity, hydration, and sun protection at the 2025 American Academy of Dermatology (AAD) Annual Meeting ["Kenvue to showcase new clinical data on skin longevity, hydration and sun protection at American Academy of Dermatology Association Meeting"(https://www.kenvue.com/media/kenvue-new-data-skin-longevity-hydration-sun-protection-aad), "Kenvue to Showcase New Clinical Data on Skin Longevity, Hydration and Sun Protection at American Academy of Dermatology Association Meeting"(https://investors.kenvue.com/financial-news/news-details/2025/Kenvue-to-Showcase-New-Clinical-Data-on-Skin-Longevity-Hydration-and-Sun-Protection-at-American-Academy-of-Dermatology-Association-Meeting/)]. Furthermore, Kenvue held a conference call regarding the "Kimberly-Clark Acquisition of Kenvue" on November 3, 2025 ["Kimberly-Clark Acquisition of Kenvue Conference Call"(https://investors.kenvue.com/events-presentations/events/event-details/2025/Kimberly-Clark-Acquisition-of-Kenvue-Conference-Call/default.aspx)].

While these events highlight Kenvue's active engagement in the past and near future, the company's investor relations page indicates that there are no upcoming events currently scheduled ["Upcoming Events"(https://investors.kenvue.com/events-presentations/default.aspx)].